Overview
Heel Spur Syndrome (HSS), is a pathology characterized by chronic inflammation and degenerative changes that affect approximately 10% of adults. Although many patients respond to conservative care, about 30% experience persistent pain. Low-dose radiation therapy (LDRT) is a well-established European method with proven anti-inflammatory and immunomodulatory effects. The ORHEELS trial aims to assess whether a Polish standard dose of 6 Gy in 6 daily fractions (fx)(5 times/week) is not inferior to the treatment with total dose of 3 Gy / fx 0,5 Gy /fractionated twice weekly. The study is designed to assess the impact of intensity of treatment (daily (5 times / week) versus twice weekly fractionation) on clinical outcomes.
Description
The aim of this study is to optimize the fractionation schedules for radiotherapy in the treatment of HSS, through a prospective randomized non-inferiority clinical trial conducted at Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland.
Purpose/Objective:
- To evaluate whether the Polish standard dose (6 Gy) achieves non-inferior therapeutic effects compared to the current European Standard Dose (3 Gy).
- To investigate whether daily fractionation is more effective than twice weekly fractionation in maintaining the desired immunomodulatory effect and avoiding a pro-inflammatory "rebound".
- To minimize the risk of stochastic effects (secondary cancers) by halving the cumulative radiation dose.
Eligibility
Inclusion Criteria:
- Patients aged 40 years or older.
- Clinically confirmed painful Heel Spur Syndrome (plantar fasciitis) persisting for at least 3 months
- No effect from previous orthopaedic, physical, or analgesic treatments.
- General performance status ZUBROD 0-3.
- Exclusion of other local conditions.
- Patient readiness for follow-up contact.
Exclusion Criteria:
- Prior radiotherapy for heel spur.
- Local use of corticosteroids within 4 weeks before planned radiotherapy.
- Previous trauma, surgery to the foot on the same side.
- Systemic diseases (eg collagen vascular disease).
- Pregnancy or breastfeeding.
- Lack of written informed consent
